Aaron D. Martin
Research Subjects
Research Interests
Aaron D. Martin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kamb
A2 Biotherapeutics Inc, Agoura Hills, California, USA
1 shared publication - Christine Yao
Innovative Targeting Solutions, Vancouver, BC, Canada
1 shared publication - Craig Pigott
Innovative Targeting Solutions, Vancouver, BC, Canada
1 shared publication - Daniel P. Nampe
A2 Biotherapeutics, Agoura Hills, CA
1 shared publication - Dora Toledo Warshaviak
A2 Biotherapeutics, Agoura Hills, CA
1 shared publication - Falene Chai
Innovative Targeting Solutions, Vancouver, BC, Canada
1 shared publication
Latest Publications
- Open Access
- 24 August 2021
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 44 (8) , 292-306
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
Next-generation T-cell therapies will likely continue to utilize T-cell receptors (TCRs) and chimeric antigen receptors (CARs) because each receptor type has advantages. TCRs often possess exceptional properties even when tested unmodified from patients’ T cells. CARs are generally less sensitive, possibly because their ligand-binding domains are grafted from antibodies selected for binding affinity or avidity and not broadly optimized for a functional response. Because of the disconnect between binding and function among these receptor types, the ultimate potential of CARs optimized for sensitivity and selectivity is not clear. Here, we focus on a thoroughly studied immuno-oncology target, the HLA-A*02/HPV-E629–38 complex, and show that CARs can be optimized by a combination of high-throughput binding screens and low-throughput functional assays to have comparable activity to clinical TCRs in acute assays in vitro. These results provide a case study for the challenges and opportunities of optimizing high-performing CARs, especially in the context of targets utilized naturally by TCRs.
- 24 August 2021
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 44 (8) , 292-306
Open AccessPotent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
Next-generation T-cell therapies will likely continue to utilize T-cell receptors (TCRs) and chimeric antigen receptors (CARs) because each receptor type has advantages. TCRs often possess exceptional properties even when tested unmodified from patients’ T cells. CARs are generally less sensitive, possibly because their ligand-binding domains are grafted from antibodies selected for binding affinity or avidity and not broadly optimized for a functional response. Because of the disconnect between binding and function among these receptor types, the ultimate potential of CARs optimized for sensitivity and selectivity is not clear. Here, we focus on a thoroughly studied immuno-oncology target, the HLA-A*02/HPV-E629–38 complex, and show that CARs can be optimized by a combination of high-throughput binding screens and low-throughput functional assays to have comparable activity to clinical TCRs in acute assays in vitro. These results provide a case study for the challenges and opportunities of optimizing high-performing CARs, especially in the context of targets utilized naturally by TCRs.